Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 17.15 USD 3.75% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Neogenomics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neogenomics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Neogenomics Inc
NASDAQ:NEO
Income from Continuing Operations
-$77.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Income from Continuing Operations
$6.2B
CAGR 3-Years
-10%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Income from Continuing Operations
$3.6B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Income from Continuing Operations
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Income from Continuing Operations
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
19%
IQVIA Holdings Inc
NYSE:IQV
Income from Continuing Operations
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
16%
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.2B USD
Industry
Life Sciences Tools & Services

NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine. By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.

NEO Intrinsic Value
12.37 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Neogenomics Inc's Income from Continuing Operations?
Income from Continuing Operations
-77.7m USD

Based on the financial report for Sep 30, 2024, Neogenomics Inc's Income from Continuing Operations amounts to -77.7m USD.

What is Neogenomics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
19%

Over the last year, the Income from Continuing Operations growth was 19%.

Back to Top